JP2023524970A5 - - Google Patents

Info

Publication number
JP2023524970A5
JP2023524970A5 JP2022567249A JP2022567249A JP2023524970A5 JP 2023524970 A5 JP2023524970 A5 JP 2023524970A5 JP 2022567249 A JP2022567249 A JP 2022567249A JP 2022567249 A JP2022567249 A JP 2022567249A JP 2023524970 A5 JP2023524970 A5 JP 2023524970A5
Authority
JP
Japan
Prior art keywords
approximately
substituted
deuterium
halogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022567249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030363 external-priority patent/WO2021225912A1/en
Publication of JP2023524970A publication Critical patent/JP2023524970A/ja
Publication of JP2023524970A5 publication Critical patent/JP2023524970A5/ja
Withdrawn legal-status Critical Current

Links

JP2022567249A 2020-05-07 2021-04-30 アミノ酸化合物による呼吸器疾患の治療 Withdrawn JP2023524970A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021674P 2020-05-07 2020-05-07
US63/021,674 2020-05-07
PCT/US2021/030363 WO2021225912A1 (en) 2020-05-07 2021-04-30 Treatment of respiratory diseases with amino acid compounds

Publications (2)

Publication Number Publication Date
JP2023524970A JP2023524970A (ja) 2023-06-14
JP2023524970A5 true JP2023524970A5 (enExample) 2024-04-30

Family

ID=78468277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567249A Withdrawn JP2023524970A (ja) 2020-05-07 2021-04-30 アミノ酸化合物による呼吸器疾患の治療

Country Status (10)

Country Link
US (1) US20230181546A1 (enExample)
EP (2) EP4520329A3 (enExample)
JP (1) JP2023524970A (enExample)
KR (1) KR20230049584A (enExample)
CN (1) CN115989235A (enExample)
AU (1) AU2021268889A1 (enExample)
CA (1) CA3173761A1 (enExample)
IL (1) IL297969A (enExample)
MX (1) MX2022013753A (enExample)
WO (1) WO2021225912A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
TW202235417A (zh) * 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
US20230028658A1 (en) * 2021-04-30 2023-01-26 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
US20240122930A1 (en) * 2022-07-09 2024-04-18 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用
WO2024235299A1 (zh) * 2023-05-17 2024-11-21 西藏海思科制药有限公司 一种羧基衍生物及其在医药上的应用
WO2025067384A1 (zh) * 2023-09-28 2025-04-03 成都微芯药业有限公司 一类氨基酸整联蛋白抑制剂、其制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502546A (en) * 1997-08-08 2002-02-01 Univ California Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
EP3925959A1 (en) * 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
JP2018514568A (ja) * 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
US10118929B2 (en) * 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
WO2018183795A1 (en) * 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
CU24684B1 (es) * 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
MX2021004173A (es) * 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.

Similar Documents

Publication Publication Date Title
JP2022526818A5 (enExample)
JP6924744B2 (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
CN104918612B (zh) 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
JP5389668B2 (ja) 皮膚浸透率の非常に高い1H−イミダゾ[4,5−c]キノリン−4−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
JP2022116170A5 (enExample)
JP2024081666A (ja) 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
ES2250200T3 (es) Derivados de naftiridina.
JP2007516983A5 (enExample)
JP2017531038A5 (enExample)
EA031746B1 (ru) СТИМУЛЯТОРЫ sGC
JP2012236838A5 (enExample)
JP2019529484A5 (enExample)
JP2018535967A5 (enExample)
SK285231B6 (sk) Použitie 6-[(imidazol-5-yl)metyl]chinolínovej zlúčeniny na prípravu farmaceutickej kompozície na liečbu artropatie
JP2023520925A5 (enExample)
JP2017514838A5 (enExample)
JP2012530703A5 (enExample)
TW201623265A (zh) 抗病毒化合物、醫藥組合物及其使用方法
IL273132A (en) Hepatitis b core protein allosteric modulators
JP5654467B2 (ja) 4−アミノ−3−(イミダゾリル)−ピラゾロ[3,4−d]ピリミジン
JP2009507909A5 (enExample)
EA037372B1 (ru) Ингибиторы репликации вирусов гриппа
SA99200059A (ar) مركبات إميدازول جديدة مستبدلة
JP2012530758A5 (enExample)
JP2019505529A5 (enExample)